NICE has published draft guidance saying the cost of using nivolumab to treat head and neck cancer is too high for routine NHS use.
NICE has assessed the benefits of using nivolumab to treat different types of cancer. For some types, such as kidney cancer, NICE has been able to recommend the drug.
For others, such as head and neck cancer, the evidence is not as strong and NICE has therefore not recommended it to be offered routinely on the NHS.
